II 

116TH CONGRESS 

1ST SESSION S. 2032 

To expand research on the cannabidiol and marihuana. 

IN THE SENATE OF THE UNITED STATES 

JUNE 27, 2019 

Mrs. FEINSTEIN (for herself, Mr. GRASSLEY, Mr. SCHATZ, Mr. DURBIN, Ms. 

KLOBUCHAR, Mr. TILLIS, Mr. KAINE, Ms. ERNST, and Mr. CRAMER) introduced the following bill; which was read twice and referred to the Committee on the Judiciary 

A BILL 

To expand research on the cannabidiol and marihuana. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE; TABLE OF CONTENTS. 

4 (a) SHORT TITLE.—This Act may be cited as the 

5 ‘‘Cannabidiol and Marihuana Research Expansion Act’’. 

6 (b) TABLE OF CONTENTS.—The table of contents for 

7 this Act is as follows: 

Sec. 1. Short title; table of contents. 

Sec. 2. Definitions. 

TITLE I—REGISTRATIONS FOR MARIHUANA RESEARCH 

Sec. 101. Marihuana research applications. 

Sec. 102. Research protocols. 

Sec. 103. Applications to manufacture marihuana for research. 


kjohnson on DSK79L0C42 with BILLS
2 

•S 2032 IS

Sec. 104. Adequate and uninterrupted supply. 

Sec. 105. Security requirements. 

Sec. 106. Prohibition against reinstating interdisciplinary review process for 

non-NIH funded researchers. 

TITLE II—DEVELOPMENT OF FDA-APPROVED DRUGS USING 

CANNABIDIOL AND MARIHUANA 

Sec. 201. Medical research on cannabidiol. 

Sec. 202. Registration for the commercial production and distribution of Food 

and Drug Administration approved drugs. 

Sec. 203. Importation of cannabidiol for research purposes. 

TITLE III—DOCTOR-PATIENT RELATIONSHIP 

Sec. 301. Doctor-patient relationship. 

TITLE IV—FEDERAL RESEARCH 

Sec. 401. Federal research. 

1 SEC. 2. DEFINITIONS. 

2 In this Act— 

3 (1) the term ‘‘appropriately registered’’ means 

4 that an individual or entity is registered under the 

5 Controlled Substances Act (21 U.S.C. 801 et seq.) 

6 to engage in the type of activity that is carried out 

7 by the individual or entity with respect to a con8 trolled substance on the schedule that is applicable 

9 to cannabidiol or marihuana, as applicable; 

10 (2) the term ‘‘cannabidiol’’ means— 

11 (A) the substance, cannabidiol, as derived 

12 from marihuana that has a tetrahydrocan13 nabinol level that is greater than 0.3 percent; 

14 and 

15 (B) the synthetic equivalent of the sub16 stance described in subparagraph (A); 


kjohnson on DSK79L0C42 with BILLS
3 

•S 2032 IS

1 (3) the terms ‘‘controlled substance’’, ‘‘dis2 pense’’, ‘‘distribute’’, ‘‘manufacture’’, ‘‘marihuana’’, 

3 and ‘‘practitioner’’ have the meanings given such 

4 terms in section 102 of the Controlled Substances 

5 Act (21 U.S.C. 802), as amended by this Act; 

6 (4) the term ‘‘covered institution of higher edu7 cation’’ means an institution of higher education (as 

8 defined in section 101 of the Higher Education Act 

9 of 1965 (20 U.S.C. 1001)) that— 

10 (A)(i) has highest or higher research activ11 ity, as defined by the Carnegie Classification of 

12 Institutions of Higher Education; or 

13 (ii) is an accredited medical school or an 

14 accredited school of osteopathic medicine; and 

15 (B) is appropriately registered under the 

16 Controlled Substances Act (21 U.S.C. 801 et 

17 seq.); 

18 (5) the term ‘‘drug’’ has the meaning given the 

19 term in section 201(g)(1) of the Federal Food, 

20 Drug, and Cosmetic Act (21 U.S.C. 321(g)(1)); 

21 (6) the term ‘‘medical research for drug devel22 opment’’ means medical research that is— 

23 (A) a preclinical study or clinical investiga24 tion conducted in accordance with section 

25 505(i) of the Federal Food, Drug, and CosVerDate Sep 11 2014 04:12 Jul 03, 2019 Jkt 089200 PO 00000 Frm 00003 Fmt 6652 Sfmt 6201 E:\BILLS\S2032.IS S2032

kjohnson on DSK79L0C42 with BILLS
4 

•S 2032 IS

1 metic Act (21 U.S.C. 355(i)) or otherwise per2 mitted by the Department of Health and 

3 Human Services to determine the potential 

4 medical benefits of marihuana or cannabidiol as 

5 a drug; and 

6 (B) conducted by a covered institution of 

7 higher education, practitioner, or manufacturer 

8 that is appropriately registered under the Con9 trolled Substances Act (21 U.S.C. 801 et seq.); 

10 and 

11 (7) the term ‘‘State’’ means any State of the 

12 United States, the District of Columbia, and any 

13 territory of the United States. 

14 TITLE I—REGISTRATIONS FOR 

15 MARIHUANA RESEARCH 

16 SEC. 101. MARIHUANA RESEARCH APPLICATIONS. 

17 Section 303(f) of the Controlled Substances Act (21 

18 U.S.C. 823(f)) is amended— 

19 (1) by redesignating paragraphs (1) through 

20 (5) as subparagraphs (A) through (E), respectively; 

21 (2) by striking ‘‘(f) The Attorney General’’ and 

22 inserting ‘‘(f)(1) The Attorney General’’; 

23 (3) by striking ‘‘Registration applications’’ and 

24 inserting the following: 

25 ‘‘(2)(A) Registration applications’’; 


kjohnson on DSK79L0C42 with BILLS
5 

•S 2032 IS

1 (4) by striking ‘‘Article 7’’ and inserting the 

2 following: 

3 ‘‘(3) Article 7’’; and 

4 (5) by inserting after paragraph (2)(A), as so 

5 designated, the following: 

6 ‘‘(B)(i) The Attorney General shall register a practi7 tioner to conduct research with marihuana if— 

8 ‘‘(I) the applicant’s research protocol— 

9 ‘‘(aa) has been reviewed and allowed— 

10 ‘‘(AA) by the Secretary of Health and 

11 Human Services under section 505(i) of 

12 the Federal Food, Drug, and Cosmetic Act 

13 (21 U.S.C. 355(i)); 

14 ‘‘(BB) by the National Institutes of 

15 Health or another Federal agency that 

16 funds scientific research; or 

17 ‘‘(CC) pursuant to sections 1301.18 

18 and 1301.32 of title 21, Code of Federal 

19 Regulations, or any successors thereto; and 

20 ‘‘(II) the applicant has demonstrated to the At21 torney General that there are effective procedures in 

22 place to adequately safeguard against diversion of 

23 the controlled substance for legitimate medical or 

24 scientific use pursuant to section 105 of the 

25 Cannabidiol and Marihuana Research Expansion 


kjohnson on DSK79L0C42 with BILLS
6 

•S 2032 IS

1 Act, including demonstrating that the security meas2 ures are adequate for storing the quantity of mari3 huana the applicant would be authorized to possess. 

4 ‘‘(ii) The Attorney General may deny an application 

5 for registration under this subparagraph only if the Attor6 ney General determines that the issuance of the registra7 tion would be inconsistent with the public interest. In de8 termining the public interest, the Attorney General shall 

9 consider the factors listed in— 

10 ‘‘(I) subparagraphs (B) through (E) of para11 graph (1); and 

12 ‘‘(II) subparagraph (A) of paragraph (1), if the 

13 applicable State requires practitioners conducting re14 search to register with a board or authority de15 scribed in such subparagraph (A). 

16 ‘‘(iii)(I) Not later than 60 days after the date on 

17 which the Attorney General receives a complete applica18 tion for registration under this subparagraph, the Attor19 ney General shall— 

20 ‘‘(aa) approve the application; or 

21 ‘‘(bb) request supplemental information. 

22 ‘‘(II) For purposes of subclause (I), an application 

23 shall be deemed complete when the applicant has sub24 mitted documentation showing that the requirements 

25 under clause (i) are satisfied. 


kjohnson on DSK79L0C42 with BILLS
7 

•S 2032 IS

1 ‘‘(iv) Not later than 30 days after the date on which 

2 the Attorney General receives supplemental information as 

3 described in clause (iii)(I)(bb) in connection with an appli4 cation described in this subparagraph, the Attorney Gen5 eral shall approve or deny the application. 

6 ‘‘(v) If an application described in this subparagraph 

7 is denied, the Attorney General shall provide a written ex8 planation of the basis of denial to the applicant.’’. 

9 SEC. 102. RESEARCH PROTOCOLS. 

10 (a) IN GENERAL.—Paragraph (2)(B) of section 303 

11 of the Controlled Substances Act (21 U.S.C. 823(f)), as 

12 amended by section 101 of this Act, is further amended 

13 by adding at the end the following: 

14 ‘‘(vi)(I) If the Attorney General grants an application 

15 for registration under clause (i), the registrant may amend 

16 or supplement the research protocol without reapplying if 

17 the registrant does not change— 

18 ‘‘(aa) the quantity or type of drug; 

19 ‘‘(bb) the source of the drug; or 

20 ‘‘(cc) the conditions under which the drug is 

21 stored, tracked, or administered. 

22 ‘‘(II)(aa) If a registrant under clause (i) seeks to 

23 change the type of drug, the source of the drug, or condi24 tions under which the drug is stored, tracked, or adminis25 tered, the registrant shall notify the Attorney General via 


kjohnson on DSK79L0C42 with BILLS
8 

•S 2032 IS

1 registered mail, or an electronic means permitted by the 

2 Attorney General, not later than 30 days before imple3 menting an amended or supplemental research protocol. 

4 ‘‘(bb) A registrant may proceed with an amended or 

5 supplemental research protocol described in item (aa) if 

6 the Attorney General does not explicitly object during the 

7 30-day period beginning on the date on which the Attorney 

8 General receives the notice under item (aa). 

9 ‘‘(cc) The Attorney General may only object to an 

10 amended or supplemental research protocol under this 

11 subclause if additional security measures are needed to 

12 safeguard against diversion or abuse. 

13 ‘‘(dd) If a registrant under clause (i) seeks to address 

14 additional security measures identified by the Attorney 

15 General under item (cc), the registrant shall notify the At16 torney General via registered mail, or an electronic means 

17 permitted by the Attorney General, not later than 30 days 

18 before implementing an amended or supplemental research 

19 protocol. 

20 ‘‘(ee) A registrant may proceed with an amended or 

21 supplemental research protocol described in item (dd) if 

22 the Attorney General does not explicitly object during the 

23 30-day period beginning on the date on which the Attorney 

24 General receives the notice under item (dd). 


kjohnson on DSK79L0C42 with BILLS
9 

•S 2032 IS

1 ‘‘(III) If a registrant under clause (i) seeks to change 

2 the quantity of marihuana needed for research, the change 

3 shall be deemed approved by the Attorney General on the 

4 date on which the registered mail return receipt is re5 turned to the registrant, or the date on which the elec6 tronic notification, as permitted by the Attorney General, 

7 is received, if the registrant submits to the Attorney Gen8 eral— 

9 ‘‘(aa) the Drug Enforcement Administration 

10 registration number of the registrant; 

11 ‘‘(bb) the quantity of marihuana already ob12 tained; and 

13 ‘‘(cc) the quantity of additional marihuana 

14 needed to complete the research. 

15 ‘‘(IV) Nothing in this clause shall limit the authority 

16 of the Secretary of Health and Human Services over re17 quirements related to research protocols, including 

18 changes in— 

19 ‘‘(aa) the method of administration of mari20 huana; 

21 ‘‘(bb) the dosing of marihuana; and 

22 ‘‘(cc) the number of individuals or patients in23 volved in research.’’. 

24 (b) REGULATIONS.—Not later than 1 year after the 

25 date of enactment of this Act, the Attorney General shall 


kjohnson on DSK79L0C42 with BILLS
10 

•S 2032 IS

1 promulgate regulations to carry out the amendment made 

2 by this section. 

3 SEC. 103. APPLICATIONS TO MANUFACTURE MARIHUANA 

4 FOR RESEARCH. 

5 (a) IN GENERAL.—Section 303 of the Controlled 

6 Substances Act (21 U.S.C. 823) is amended— 

7 (1) by redesignating subsections (c) through (k) 

8 as subsections (d) through (l), respectively; 

9 (2) by inserting after subsection (b) the fol10 lowing: 

11 ‘‘(c)(1)(A) As it relates to applications to manufac12 ture marihuana for research purposes, if the Attorney 

13 General places a notice in the Federal Register to increase 

14 the number of entities registered under this Act to manu15 facture marihuana to supply appropriately registered re16 searchers in the United States, the Attorney General shall, 

17 not later than 60 days after the date on which the Attor18 ney General receives a completed application— 

19 ‘‘(i) approve the application; or 

20 ‘‘(ii) request supplemental information. 

21 ‘‘(B) For purposes of subparagraph (A), an applica22 tion shall be deemed complete when the applicant has sub23 mitted documentation showing each of the following: 

24 ‘‘(i) The requirements designated in the notice 

25 in the Federal Register are satisfied. 


kjohnson on DSK79L0C42 with BILLS
11 

•S 2032 IS

1 ‘‘(ii) The requirements under this Act are satis2 fied. 

3 ‘‘(iii) The applicant will limit the transfer and 

4 sale of any marihuana manufactured under this sub5 section— 

6 ‘‘(I) to researchers who are registered 

7 under this Act to conduct research with con8 trolled substances in schedule I; and 

9 ‘‘(II) for purposes of use in preclinical re10 search or in a clinical investigation pursuant to 

11 an investigational new drug exemption under 

12 505(i) of the Federal Food, Drug, and Cos13 metic Act (21 U.S.C. 355(i)). 

14 ‘‘(iv) The applicant will transfer or sell any 

15 marihuana manufactured under this subsection only 

16 with prior, written consent for the transfer or sale 

17 by the Attorney General. 

18 ‘‘(v) The applicant has completed the applica19 tion and review process under subsection (a) for the 

20 bulk manufacture of controlled substances in sched21 ule I. 

22 ‘‘(vi) The applicant has established and begun 

23 operation of a process for storage and handling of 

24 controlled substances in schedule I, including for in25 ventory control and monitoring security in accordVerDate Sep 11 2014 04:12 Jul 03, 2019 Jkt 089200 PO 00000 Frm 00011 Fmt 6652 Sfmt 6201 E:\BILLS\S2032.IS S2032

kjohnson on DSK79L0C42 with BILLS
12 

•S 2032 IS

1 ance with section 105 of the Cannabidiol and Mari2 huana Research Expansion Act. 

3 ‘‘(vii) The applicant is licensed by each State in 

4 which the applicant will conduct operations under 

5 this subsection, to manufacture marihuana, if that 

6 State requires such a license. 

7 ‘‘(C) Not later than 30 days after the date on which 

8 the Attorney General receives supplemental information 

9 requested under subparagraph (A)(ii) with respect to an 

10 application, the Attorney General shall approve or deny 

11 the application. 

12 ‘‘(2) If an application described in this subsection is 

13 denied, the Attorney General shall provide a written expla14 nation of the basis of denial to the applicant.’’; 

15 (3) in subsection (h)(2), as so redesignated, by 

16 striking ‘‘subsection (f)’’ each place it appears and 

17 inserting ‘‘subsection (g)’’; 

18 (4) in subsection (j)(1), as so redesignated, by 

19 striking ‘‘subsection (d)’’ and inserting ‘‘subsection 

20 (e)’’; and 

21 (5) in subsection (k), as so redesignated, by 

22 striking ‘‘subsection (f)’’ each place it appears and 

23 inserting ‘‘subsection (g)’’. 

24 (b) TECHNICAL AND CONFORMING AMENDMENTS.— 


kjohnson on DSK79L0C42 with BILLS
13 

•S 2032 IS

1 (1) The Controlled Substances Act (21 U.S.C. 

2 801 et seq.) is amended— 

3 (A) in section 102 (21 U.S.C. 802)— 

4 (i) in paragraph (16)(B)— 

5 (I) in clause (i), by striking ‘‘or’’ 

6 at the end; 

7 (II) by redesignating clause (ii) 

8 as (iii); and 

9 (III) by inserting after clause (i) 

10 the following: 

11 ‘‘(ii) the synthetic equivalent of hemp-de12 rived cannabidiol that contains less than 0.3 

13 percent tetrahydrocannabinol; or’’; 

14 (ii) in paragraph (52)(B)— 

15 (I) by striking ‘‘303(f)’’ each 

16 place it appears and inserting 

17 ‘‘303(g)’’; and 

18 (II) in clause (i), by striking 

19 ‘‘(d), or (e)’’ and inserting ‘‘(e), or 

20 (f)’’; and 

21 (iii) in paragraph (54), by striking 

22 ‘‘303(f)’’ each place it appears and insert23 ing ‘‘303(g)’’; 


kjohnson on DSK79L0C42 with BILLS
14 

•S 2032 IS

1 (B) in section 304 (21 U.S.C. 824), by 

2 striking ‘‘303(g)(1)’’ each place it appears and 

3 inserting ‘‘303(h)(1)’’; 

4 (C) in section 307(d)(2) (21 U.S.C. 

5 827(d)(2)), by striking ‘‘303(f)’’ and inserting 

6 ‘‘303(g)’’; 

7 (D) in section 311(h) (21 U.S.C. 831(h)), 

8 by striking ‘‘303(f)’’ each place it appears and 

9 inserting ‘‘303(g)’’; 

10 (E) in section 401(h)(2) (21 U.S.C. 

11 841(h)(2)), by striking ‘‘303(f)’’ each place it 

12 appears and inserting ‘‘303(g)’’; 

13 (F) in section 403(c)(2)(B) (21 U.S.C. 

14 843(c)(2)(B)), by striking ‘‘303(f)’’ and insert15 ing ‘‘303(g)’’; and 

16 (G) in section 512(c)(1) (21 U.S.C. 

17 882(c)(1)) by striking ‘‘303(f)’’ and inserting 

18 ‘‘303(g)’’. 

19 (2) Section 1008(c) of the Controlled Sub20 stances Import and Export Act (21 U.S.C. 958(c)) 

21 is amended— 

22 (A) in paragraph (1), by striking ‘‘303(d)’’ 

23 and inserting ‘‘303(e)’’; and 

24 (B) in paragraph (2)(B), by striking 

25 ‘‘303(h)’’ and inserting ‘‘303(i)’’. 


kjohnson on DSK79L0C42 with BILLS
15 

•S 2032 IS

1 (3) Title V of the Public Health Service Act (42 

2 U.S.C. 290aa et seq.) is amended— 

3 (A) in section 520E–4(c) (42 U.S.C. 

4 290bb–36d(c)), by striking ‘‘303(g)(2)(B)’’ and 

5 inserting ‘‘303(h)(2)(B)’’; and 

6 (B) in section 544(a)(3) (42 U.S.C. 

7 290dd–3(a)(3)), by striking ‘‘303(g)’’ and in8 serting ‘‘303(h)’’. 

9 SEC. 104. ADEQUATE AND UNINTERRUPTED SUPPLY. 

10 On an annual basis, the Attorney General shall assess 

11 whether there is an adequate and uninterrupted supply of 

12 marihuana, including of specific strains, for research pur13 poses. 

14 SEC. 105. SECURITY REQUIREMENTS. 

15 (a) IN GENERAL.—An individual or entity engaged 

16 in researching marihuana or its components shall store it 

17 in a securely locked, substantially constructed cabinet. 

18 (b) REQUIREMENTS FOR OTHER MEASURES.—Any 

19 other security measures required by the Attorney General 

20 to safeguard against diversion shall be consistent with 

21 those required for practitioners conducting research on 

22 other controlled substances in schedules I and II in section 

23 202(c) of the Controlled Substances Act (21 U.S.C. 

24 812(c)) that have a similar risk of diversion and abuse. 


kjohnson on DSK79L0C42 with BILLS
16 

•S 2032 IS

1 SEC. 106. PROHIBITION AGAINST REINSTATING INTER2 DISCIPLINARY REVIEW PROCESS FOR NON3 NIH FUNDED RESEARCHERS. 

4 The Secretary of Health and Human Services may 

5 not— 

6 (1) reinstate the Public Health Service inter7 disciplinary review process described in the guidance 

8 entitled ‘‘Guidance on Procedures for the Provision 

9 of Marijuana for Medical Research’’ (issued on May 

10 21, 1999); or 

11 (2) require another review of scientific protocols 

12 that is applicable only to research on marihuana or 

13 its components. 

14 TITLE II—DEVELOPMENT OF 

15 FDA-APPROVED DRUGS 

16 USING CANNABIDIOL AND 

17 MARIHUANA 

18 SEC. 201. MEDICAL RESEARCH ON CANNABIDIOL. 

19 Notwithstanding any provision of the Controlled Sub20 stances Act (21 U.S.C. 801 et seq.), the Safe and Drug21 Free Schools and Communities Act (20 U.S.C. 7101 et 

22 seq.), chapter 81 of title 41, United States Code, or any 

23 other Federal law, an appropriately registered covered in24 stitution of higher education, a practitioner, or a manufac25 turer may manufacture, distribute, dispense, or possess 

26 marihuana or cannabidiol if the marihuana or cannabidiol 


kjohnson on DSK79L0C42 with BILLS
17 

•S 2032 IS

1 is manufactured, distributed, dispensed, or possessed, re2 spectively, for purposes of medical research for drug devel3 opment or subsequent commercial production in accord4 ance with section 202. 

5 SEC. 202. REGISTRATION FOR THE COMMERCIAL PRODUC6 TION AND DISTRIBUTION OF FOOD AND 

7 DRUG ADMINISTRATION APPROVED DRUGS. 

8 The Attorney General shall register an applicant to 

9 manufacture or distribute cannabidiol or marihuana for 

10 the purpose of commercial production of a drug containing 

11 or derived from marihuana that is approved by the Sec12 retary of Health and Human Services under section 505 

13 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 

14 355), in accordance with the applicable requirements 

15 under subsection (a) or (b) of section 303 of the Con16 trolled Substances Act (21 U.S.C. 823). 

17 SEC. 203. IMPORTATION OF CANNABIDIOL FOR RESEARCH 

18 PURPOSES. 

19 The Controlled Substances Import and Export Act 

20 (21 U.S.C. 951 et seq.) is amended— 

21 (1) in section 1002(a) (21 U.S.C. 952(a))— 

22 (A) in paragraph (1), by striking ‘‘and’’ at 

23 the end; 

24 (B) in paragraph (2)(C), by inserting 

25 ‘‘and’’ after ‘‘uses,’’; and 


kjohnson on DSK79L0C42 with BILLS
18 

•S 2032 IS

1 (C) inserting before the undesignated mat2 ter following paragraph (2)(C) the following: 

3 ‘‘(3) such amounts of marihuana or cannabidiol 

4 (as defined in section 2 of the Cannabidiol and Mar5 ihuana Research Expansion Act) as are— 

6 ‘‘(A) approved for medical research for 

7 drug development (as such terms are defined in 

8 section 2 of the Cannabidiol and Marihuana Re9 search Expansion Act), or 

10 ‘‘(B) necessary for registered manufactur11 ers to manufacture drugs containing marihuana 

12 or cannabidiol that have been approved for use 

13 by the Commissioner of Food and Drugs under 

14 the Federal Food, Drug, and Cosmetic Act (21 

15 U.S.C. 301 et seq.),’’; and 

16 (2) in section 1007 (21 U.S.C. 957), by amend17 ing subsection (a) to read as follows: 

18 ‘‘(a)(1) Except as provided in paragraph (2), no per19 son may— 

20 ‘‘(A) import into the customs territory of the 

21 United States from any place outside thereof (but 

22 within the United States), or import into the United 

23 States from any place outside thereof, any controlled 

24 substance or list I chemical, or 


kjohnson on DSK79L0C42 with BILLS
19 

•S 2032 IS

1 ‘‘(B) export from the United States any con2 trolled substance or list I chemical, 

3 unless there is in effect with respect to such person 

4 a registration issued by the Attorney General under 

5 section 1008, or unless such person is exempt from 

6 registration under subsection (b). 

7 ‘‘(2) Paragraph (1) shall not apply to the im8 port or export of marihuana or cannabidiol (as de9 fined in section 2 of the Cannabidiol and Marihuana 

10 Research Expansion Act) that has been approved 

11 for— 

12 ‘‘(A) medical research for drug develop13 ment authorized under section 201 of the 

14 Cannabidiol and Marihuana Research Expan15 sion Act; or 

16 ‘‘(B) use by registered manufacturers to 

17 manufacture drugs containing marihuana or 

18 cannabidiol that have been approved for use by 

19 the Commissioner of Food and Drugs under the 

20 Federal Food, Drug, and Cosmetic Act (21 

21 U.S.C. 301 et seq.).’’. 


kjohnson on DSK79L0C42 with BILLS
20 

•S 2032 IS

1 TITLE III—DOCTOR-PATIENT 

2 RELATIONSHIP 

3 SEC. 301. DOCTOR-PATIENT RELATIONSHIP. 

4 It shall not be unlawful for a State-licensed physician 

5 to discuss— 

6 (1) the currently known potential harms and 

7 benefits of marihuana derivatives, including 

8 cannabidiol, as a treatment with the legal guardian 

9 of the patient of the physician if the patient is a 

10 child; or 

11 (2) the currently known potential harms and 

12 benefits of marihuana and marihuana derivatives, 

13 including cannabidiol, as a treatment with the pa14 tient or the legal guardian of the patient of the phy15 sician if the patient is a legal adult. 

16 TITLE IV—FEDERAL RESEARCH 

17 SEC. 401. FEDERAL RESEARCH. 

18 (a) IN GENERAL.—Not later than 1 year after the 

19 date of enactment of this Act, the Secretary of Health and 

20 Human Services, in coordination with the Director of the 

21 National Institutes of Health and the heads of other rel22 evant Federal agencies, shall submit to the Caucus on 

23 International Narcotics Control, the Committee on the Ju24 diciary, and the Committee on Health, Education, Labor, 

25 and Pensions of the Senate and the Committee on Energy 


kjohnson on DSK79L0C42 with BILLS
21 

•S 2032 IS

1 and Commerce and the Committee on the Judiciary of the 

2 House of Representatives a report on— 

3 (1) the potential therapeutic effects of 

4 cannabidiol or marihuana on serious medical condi5 tions, including intractable epilepsy; 

6 (2) the potential effects of marihuana, includ7 ing— 

8 (A) the effect of increasing delta-9- 

9 tetrahydrocannabinol levels on the human body 

10 and developing adolescent brains; and 

11 (B) the effect of various delta-9- 

12 tetrahydrocannabinol levels on cognitive abili13 ties, such as those that are required to operate 

14 motor vehicles or other heavy equipment; and 

15 (3) the barriers associated with researching 

16 marihuana or cannabidiol in States that have legal17 ized the use of such substances, which shall in18 clude— 

19 (A) recommendations as to how such bar20 riers might be overcome, including whether pub21 lic-private partnerships or Federal-State re22 search partnerships may or should be imple23 mented to provide researchers with access to 

24 additional strains of marihuana and 

25 cannabidiol; and 


kjohnson on DSK79L0C42 with BILLS
22 

•S 2032 IS

1 (B) recommendations as to what safe2 guards must be in place to verify— 

3 (i) the levels of tetrahydrocannabinol, 

4 cannabidiol, or other cannabinoids con5 tained in products obtained from such 

6 States is accurate; and 

7 (ii) that such products do not contain 

8 harmful or toxic components. 

9 (b) ACTIVITIES.—To the extent practicable, the Sec10 retary of Health and Human Services, either directly or 

11 through awarding grants, contacts, or cooperative agree12 ments, shall expand and coordinate the activities of the 

13 National Institutes of Health and other relevant Federal 

14 agencies to better determine the effects of cannabidiol and 

15 marihuana, as outlined in the report submitted under 

16 paragraphs (1) and (2) of subsection (a). 

Æ 


kjohnson on DSK79L0C42 with BILLS